Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase i

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2791-2797

  Fouliard, Sylvain ^a   Robert, Renata ^a   Jacquet Bescond, Anne ^a   Du Rieu, Quentin Chalret ^a   Balasubramanian, Sriram ^b   Loury, David ^b   Loriot, Yohann ^c   Hollebecque, Antoine ^c   Kloos, Ioana ^a   Soria, Jean Charles ^c   Chenel, Marylore ^a   Depil, Stéphane ^a  

^a IRIS Institut de Recherches Internationales Servier   (France)

^b PHARMACYCLICS INC   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Decision support techniques; Drug administration; Mechanism of action; Pharmacodynamics; Pharmacokinetics; schedule Drug toxicity

Indexed keywords

ABEXINOSTAT;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MEGADOSE; HUMAN; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE DRUG TOXICITY; MECHANISM OF ACTION; PHARMACODYNAMICS; PHARMACOKINETICS;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; BENZOFURANS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FRANCE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MAXIMUM TOLERATED DOSE; MODELS, BIOLOGICAL; NEOPLASMS; PLATELET COUNT; THROMBOCYTOPENIA;

EID: 84881085302     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.009     Document Type: Article

References (22)

1. S.Y. Archer, S. Meng, A. Shei, and R.A. Hodin P21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells Proc Natl Acad Sci U S A 95 12 1998 6791 6796
2. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 1 2006 38 51
3. P. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, and W.K. Kelly Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 3 2001 194 202
4. D.S. Schrump Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications Clin Cancer Res 15 12 2009 3947 3957
5. M.R. Acharya, A. Sparreboom, J. Venitz, and W.D. Figg Rational development of histone deacetylase inhibitors as anticancer agents: a review Mol Pharmacol 68 4 2005 917 932
6. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 2006 769 784
7. C.F. Deroanne, K. Bonjean, and S. Servotte Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling Oncogene 21 3 2002 427 436
8. K.B. Glaser HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 5 2007 659 671
9. V.M. Richon, J. Garcia-Vargas, and J.S. Hardwick Development of vorinostat: current applications and future perspectives for cancer therapy Cancer Lett 280 2 2009 201 210
10. H. Matsuoka, A. Unami, and T. Fujimura Mechanisms of HDAC inhibitor-induced thrombocytopenia Eur J Pharmacol 571 2-3 2007 88 96
11. C. Iancu-Rubin, D. Gajzer, G. Mosoyan, F. Feller, J. Mascarenhas, and R. Hoffman Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation Exp Hematol 40 7 2012 564 574
12. J.J. Buggy, Z.A. Cao, and K.E. Bass CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Mol Cancer Ther 5 5 2006 1309 1317
13. Janc JW. S78454 - in vitro biochemical characterization of CRA-024781; 2005.
14. CTEP. Common Terminology Criteria for Adverse Events v4.0 - CTCAE; 2013. http://ctep.cancer.gov [cited 2013 Apr 24].
15. L.E. Friberg, A. Henningsson, H. Maas, L. Nguyen, and M.O. Karlsson Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 24 2002 4713 4721
16. K. Brendel, E. Comets, C. Laffont, C. Laveille, and F. Mentre Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide Pharm Res 23 9 2006 2036 2049
17. L.E. Friberg, C.J. Brindley, M.O. Karlsson, and A.J. Devlin Models of schedule dependent haematological toxicity of 2′-deoxy-2′- methylidenecytidine (DMDC) Eur J Clin Pharmacol 56 8 2000 567 574
18. L.E. Friberg, A. Freijs, M. Sandstrom, and M.O. Karlsson Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats J Pharmacol Exp Ther 295 2 2000 734 740
19. H. Minami, Y. Sasaki, and N. Saijo Indirect-response model for the time course of leukopenia with anticancer drugs Clin Pharmacol Ther 64 5 1998 511 521
20. W.C. Zamboni, D.Z. D'Argenio, and C.F. Stewart Pharmacodynamic model of topotecan-induced time course of neutropenia Clin Cancer Res 7 8 2001 2301 2308
21. C.R. Giver, D.L. Jaye, E.K. Waller, J.L. Kaufman, and S. Lonial Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes Leukemia 25 2 2011 362 365
22. R.M. Savic, and M.O. Karlsson Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions AAPS J 11 3 2009 558 569